{{Rsnum
|rsid=10983320
|Gene=ASTN2
|Chromosome=9
|position=116721410
|Orientation=plus
|GMAF=0.4288
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=ASTN2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 31.0 | 46.9 | 22.1
| HCB | 44.0 | 44.0 | 11.9
| JPT | 46.4 | 45.5 | 8.0
| YRI | 45.9 | 43.8 | 10.3
| ASW | 30.9 | 52.7 | 16.4
| CHB | 44.0 | 44.0 | 11.9
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 31.2 | 53.2 | 15.6
| MEX | 15.5 | 46.6 | 37.9
| MKK | 35.9 | 49.4 | 14.7
| TSI | 24.8 | 53.5 | 21.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs10983320
|Name_s=
|Gene_s=ASTN2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 89. Study population/ethnicity: 89 Yorubans. Significance metric(s): p = 0.00007. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109322
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10983320
|overall_frequency_n=48
|overall_frequency_d=128
|overall_frequency=0.375
|n_genomes=32
|n_genomes_annotated=0
|n_haplomes=39
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}